Our findings suggest that CTSD is significantly over-expressed in the serum of AML patients and that its expression is closely related to disease progression, treatment response, and prognosis, indicating that CTSD may serve as a potential diagnostic and prognostic biomarker for AML. This evidence concerns the gene CTSD and acute myeloid leukemia.